The IC50 was approximately 5 μM concentration of canertinib in both CD18/HPAF and Capan-1 pancreatic cancer cells, hence, these doses were utilized for subsequent drug analysis. This evidence concerns the gene ITGB2 and familial pancreatic carcinoma.